Global Musculoskeletal Diseases Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Type (Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia and Others), Type Of Molecules (Biologics and Small Molecules) and Region – Industry Forecast From (2024 to 2029)

Updated On: January, 2024
ID: 7165
Pages: 175

 Musculoskeletal Diseases Market Size (2024 to 2029)

The global musculoskeletal diseases market is predicted to grow at a CAGR of 6.12% from 2024 to 2029. The market size is anticipated to grow to USD 7.13 billion by 2029 from USD 5.30 billion in 2024.

Current Scenario of the Musculoskeletal Diseases Market

Musculoskeletal diseases are injuries and disorders which affect the musculoskeletal system of the human body. The injuries and disorders include muscles, ligaments, nerves, tendons, spinal discs, and cartilage. The most common musculoskeletal diseases are osteoarthritis, gout, back pain, osteoporosis, and rheumatoid arthritis. Muscle tissue gets damaged with the wear and tear of daily activities, which causes musculoskeletal pain. The drugs for musculoskeletal disease treatment are muscle relaxants, anti-inflammatory drugs, antipyretics, and corticosteroids commonly used worldwide. Many players dominate the musculoskeletal diseases market because of the highly fragmented and competitive landscape. Therefore, the musculoskeletal diseases market has been examined to present an in-depth market assessment based on past and present performance status.


YOY rise in the incidence of musculoskeletal diseases is primarily propelling the musculoskeletal diseases market worldwide.

Musculoskeletal diseases cause increased workplace pressure, low fitness and health habits, and improper postures. Across the world, the number of people suffering from musculoskeletal conditions is growing significantly. As per the reports published by WHO, across the world, a total of 1.71 billion people are suffering from musculoskeletal conditions. According to recent reports, ligaments, tendons, cartilage, and spinal discs are musculoskeletal injuries and disorders rapidly increasing globally, expected to drive the market growth.

Increasing awareness among the people about musculoskeletal diseases, developing efficient and advanced technologies in developed countries, and commercialization of pipeline drugs are other primary factors driving the market growth.

Moreover, encouraging global government initiatives, increasing healthcare expenditure, and adopting musculoskeletal disease drugs are expected to favor market growth. Besides, the significant presence of unmet medical needs in developing countries is more likely to support market growth. Therefore, adopting musculoskeletal disease drugs provides lucrative opportunities for market players in emerging countries to propel the musculoskeletal diseases market.Technological advancements in the field of treatment help market growth.

The market is growing due to the continuous development of technologies used to diagnose and treat musculoskeletal diseases. Diagnosis instruments for musculoskeletal problems are now more flexible and have more feasibility. The latest techniques, like biologics, small molecules, stem cell research, and others, help improve the accuracy of treatment procedures and drugs. Procedures such as organ-on-a-chip, lab-on-a-chip, orthobiologics, gene therapy, etc., help improve treatment options for musculoskeletal disorders. Additionally, techniques like bone grafting help fix fractured bones. Therefore, better care services and intensive research and development are expected to support market expansion. 


High costs associated with the R&D, stringent government rules, and a complex government approval process is expected to impede the musculoskeletal diseases market growth. In addition, the primary concern for the hospitals is that the risk of side effects of musculoskeletal disease treatment hinders market growth.

Impact of COVID-19 on the global musculoskeletal diseases market

The emergence of the outbreak of covid-19 has shown a positive and negative impact on the pharmaceutical and life sciences industries. The pandemic and the winding down of the activities have affected many industry participants'' operations and financial results. In addition, the outbreak of COVID-19 has negatively impacted the musculoskeletal disease market in the first half of 2020. Due to the sudden introduction of the lockdown, the distribution channel was disrupted during the pandemic's early periods. Moreover, musculoskeletal disease treatments were stopped and postponed as the world focused on fighting against the virus.

However, the relief of the lockdown positively impacts market growth. Small and medium clinics have started treating musculoskeletal disease patients. As a result, the demand for musculoskeletal disease drugs has increased, and the supply chain has been improved. In addition, industry manufacturers are coming up with advanced disease drugs to ensure that patients opt for better treatments and effects. As a result, the market is anticipated to witness promising growth in the coming years.





Market Size Available

2024 to 2029

Base Year


Forecast Period

2024 to 2029

Segments Covered

By Type, Type of Molecules, Treatment, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leader Profiled

AbGenomics International, AB Sciences, Ablynx, Akron Molecules, Johnson & Johnson, F. Hoffmann-La Roche, Pfizer.



Musculoskeletal Diseases Market  By Type

Based on type, rheumatoid arthritis has a high prevalence and therefore had the largest share of the market in 2021. The increasing geriatric population and rising chronic inflammatory disorders propel market growth. In addition, the uptake of new products in IL-6 and JAH inhibitors and the approval and launch of pipeline therapies are expected to increase the segment's growth.

However, the osteoarthritis segment is also expected to help the market grow. It is a prevalent condition due to the cartilage wearing off on bones, especially in the hips, knees, and hands. Around 32.5 million U.S. adults are affected by osteoarthritis, according to CDC. Therefore, the condition's prevalence is expected to support its dominance in the market. 

Additionally, ankylosing spondylitis segment is also expected to grow during the forecast period due to the rising cases of spondylitis worldwide. 

Musculoskeletal Diseases Market By Type of Molecules

Based on the type of molecules, the biologics segment is expected to have the largest market share. Biologics have a complex structure that does not allow easy identification or characterization, which drives this segment. However, the biologics drugs are robust and work very well for patients with Rheumatoid arthritis, psoriatic, and other inflammatory arthritis. In addition, the products of biologics are heavily used in biopharmaceuticals for the creation of drugs and experimentation, further promoting the segment's growth.

However, the small molecules segment is also expected to grow during the forecast period due to the application of small molecules in drug discovery and finding information about gene expression. Small molecules are organic compounds with low molecular weight and can efficiently penetrate and react within intracellular levels like the cytoplasm. This tremendous advantage of the segment promises it a bright revenue in the future. 

Musculoskeletal Diseases Market  By Treatment

Based on the treatment, the corticosteroids segment held the largest market share in 2021. The segment's growth is expected to be driven by the growth factors such as increasing disposable income, advanced corticosteroids, and riding investments by the government to develop hospital infrastructure to ensure better treatments.

However, the synthetic bone graft and biologics market segments are expected to grow significantly during the forecast period. These two segments are relatively new and emerging, with research and development of many technologies to apply the treatment process supporting their growth. Furthermore, bone grafting is a beneficial process in case of bone fractures, and biologics help fix musculoskeletal issues. Therefore, the rising cases of accidents leading to fractures are supporting the growth of the segments. 


Geographically, the North American musculoskeletal diseases market had the largest share of the world market in 2021, owing to the increased use of biological drugs for treating various musculoskeletal diseases, increased access to medical and healthcare facilities, and the introduction of novel biologics. The rising uptake of existing biologics drugs for various musculoskeletal disease treatments, increasing need for drug development, and novel biologics are expected to drive market growth in this region. In addition, access to this region's medical and healthcare facilities and increasing healthcare spending propel the musculoskeletal disease market.

The European musculoskeletal diseases market was the second-largest regional market and is anticipated to grow at a robust CAGR during the forecast period. An increase in pressure in workplaces leads to various musculoskeletal diseases. In addition, low fitness, health habits, and improper postures create the demand for musculoskeletal disease treatments, leading to market growth.

The Asia Pacific musculoskeletal diseases market is considered the fastest-growing regional market globally and is predicted to register the highest CAGR during the forecast period. Emerging countries, such as India and China, are experiencing muscular disorders due to increased work pressure. These countries witness significant market growth due to the rapid adoption of advanced treatments for musculoskeletal diseases. However, the market is projected to record better growth over the forecast period.

The musculoskeletal diseases market in Latin America is expected to grow at a CAGR of 7.03% during the forecast period.

The musculoskeletal diseases market in Middle East Africa is projected to witness substantial growth over the forecast period with influential growth factors.


Some of the notable companies dominating the global musculoskeletal diseases market profiled in this report are AbGenomics International, AB Sciences, Ablynx, Akron Molecules, Johnson & Johnson, F. Hoffmann-La Roche, Pfizer, Eli Lilly, Adheron, Alder BioPharmaceuticals, Bioiberica, Bone Therapeutics, Edding Pharm, Boehringer Ingelheim, Can-Fite BioPharma, Celltrion, Celgene Corp., Cellular Biomedicine, ChemoCentryx, Cerapedics, Eupraxia Pharmaceuticals, and GlaxoSmithKline.


  • In September 2022, the highest level of validation offered by the Validation Institute, Program Validation, was awarded to Kaia Health, making it the first and (as of this writing) only MSK digital therapy as well as the second digital health enterprise in history. The validation honors Kaia Health's meticulous, evidence-based digital therapy strategy for treating musculoskeletal problems, producing best-in-class results in terms of money and health. 

  • In October 2022, VSS Capital Partners ("VSS"), a private investment company that makes investments in the healthcare, education, and business services sectors, announced today that it has invested in Center for Rheumatology ("CFR" or "the Company"), a platform for rheumatology that provides a full range of services for the treatment of various chronic rheumatic diseases. 

  • In September 2022, Massachusetts Business Magazine for Vermonters, musculoskeletal health is a common health problem and essential to overall well-being. In light of this, Blue Cross and Blue Shield of Vermont have partnered with Hinge Health to provide its members with a digital musculoskeletal (MSK) clinic, which will help lower the need for operations and opiate use. 


This research report on the global musculoskeletal diseases market is segmented and sub-segmented into the following categories.

By Type

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Osteoporosis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Fibromyalgia
  • Others

By Type of Molecules

  • Biologics
  • Small Molecules

By Treatment

  • Biologics
  • Corticosteroids
  • Parathyroid Hormone
  • Protein Therapy
  • Selective Estrogen Receptor Modulators
  • Synthetic Bone Graft
  • Composite Grafts
  • Demineralized Bone Matrix
  • BMPS

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa 

Please wait. . . . Your request is being processed

Frequently Asked Questions

How big is the musculoskeletal diseases market?

The global musculoskeletal diseases market size was worth USD 4.39 billion in 2024 and is forecasted to reach USD 6.72 billion by 2029.

What is the growth rate of the musculoskeletal diseases market in the APAC region?

The APAC musculoskeletal diseases market is expected to showcase a CAGR of 8.05% from 2024 to 2029, which is also the highest among all the regions.

How much was the musculoskeletal diseases market worth in Europe in 2023?

In 2023, the Europe musculoskeletal diseases market was valued at USD 4.99 billion in 2023.

What are some of the leading players in the musculoskeletal diseases market?

AbGenomics International, AB Sciences, Ablynx, Akron Molecules, Johnson & Johnson, F. Hoffmann-La Roche, Pfizer, Eli Lilly, Adheron, Alder BioPharmaceuticals, Bioiberica, Bone Therapeutics, Edding Pharm, Boehringer Ingelheim, Can-Fite BioPharma, Celltrion, Celgene Corp., Cellular Biomedicine, ChemoCentryx, Cerapedics, Eupraxia Pharmaceuticals, and GlaxoSmithKline are some of the notable players in the market,

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample